Doc. 1.

Ministry of Health, Welfare and Sport
Py 't•tel

3. Return addrett Postbus 20250 2500 El Den Haag
DO CuratIve Care

Shine Medical Technologies, LLC
Attn Dr. Gregory Pieter
101 E. Mllwaukee Street, Suite 600
lANESVILLE, WI 53545
USA

Address for vlaken:
Pareastusplein 5
2511 VX Den Haag
T 070 340 79 11
f 070 340 78 34
Postbus 20350
2500 El Den Haag
rrynr.rijksoverheirl.n1
Information

10.2.e.
Date
Subject

2 5 JAN, 2021
A warm welcome to SHINE

Dear Mr. Plefer,
The Dutch government is very pleased with the Interest of SHINE Medical
Technologies In the Netherlands for the establishment of its European fadilties.
The Netherlands has a long lasting history in the research, development and
manufacturing of medical isotopes, and we are convinced that SHINE, with lts
Innovative technology, would be an important addition to the Dutch ecosystem in
nuclear medicine.

Our reference
217386
Your reference
All correspondente addressed
to the postai address quoting
date end rererence of tras
lottor.

Last year I had the pleasure to meet Mr. Eric Schutt and Mr. Herrie Buurlage and
hear about the plans of SHINE Medical Technologies. This has convinced me of the
great potential SHINE provides for the future of nuclear medicine.
You have informed me that SHINE plans to open a second production site on this
side of the Atlantic. We are proud that, after an extensive search, you have
selected the province of Groningen as one of two main contenders for the
European location. We have been informed about the constructive cooperation
between Groningen and your team and can assure you that the Groningen region
is an excellent cholcel
The addition of SHINE to the Dutch nudear medicine landscape woukl yield new
opportunities for collaboration and would make the Dutch nuclear knowledgeinfrastrudure one of the strongest in the world. This is not only profitable for
patients, here and elsewhere, but also from a business perspedive for both SHINE
and the Netherlands. In this respect, I would also like to point out that a location
in the Netherlands entails unrestricted access to the European market. 1 view
SHINE as an important and very promising Innovator In the field of medical radioisotopes and therefore truly believe that SHINE and Groningen would make a
great match.
In our conversations you underlined your concern about a level playing field for
SHINE and emphasized your request for a guarantee that the Dutch government is
committed to this principle. I can wholeheartedly confirm that we as government
wil! be fulty compliant to this, both by choice and by tegel obligation.

Page 1 of 2

trg,._t$
t_1Wfl,

As stated In my letter to parliament of 9 December 2020, I want to make sure
that SHINE will have equal opportunities, which is In line with a motion
unanimously adopted by the House of Representatives on 27 October 2020,
requesting to ensure a level playing field for your company.

Directoraat Generaal
Curatieve Zorg
Directie Geneesmidd en Med.
Technologie
Team B

Furthermore, Dutch legislation guarantees that unfair competition cannot take
place between companies financed by the government and private market porties.
The Competition Act and the associated Market and Government Decree sets rules
to ensure that governments and companies controlled by the government do not
disrupt the market. The Netherlands Is also committed to upholding EU
competition rules that guide the internal market. The principle of a genuine level
playing field is central to this. This means that enterprises that are active on the
European Internat market have to comply with competition rules which are
enforced by national and European authorities. It also means that the Dutch
authorities have to comply to the State aid rules and regulations of the European
Treaties and the European Commission.
Speclfically in the field of nuclear medicine, the Netherlands complies to the
principles set forth In the policy approach reieased In lune 2011 by the High-Level
Group on the Security of Supply of Medical Radiolsotopes (the HLG-MR principles)
to ensure the long-term secure supply of medical radiolsotopes, which were
formally endorsed by the Organization for Economic Co-operation and
Development's (OECD) Steering Committee for Nuclear Energy on 28 April 2011. I
hope that these guarantees will earn your trust for opting for the Netherlands for
SHINE's European facility.
As you know, I am looking for possibilities to grant a loon to SHINE, and invite you
to discuss with us the conditions on which both SHINE and the Ministry can agree.
I am currently exploring the possibilities of a joint effort with the Investment &
Development Agency for the Northern Netherlands (NOM) and the Province of
Groningen who have already committed to a support of 10 million euros. I hope
that this Is testament to our trust In the potential of SHINE. Furthermore, I would
lIke to offer the assistante of the Ministry of Health, Welfare and Sports when
contacting local or regional governmental bodies or agencies. The Ministry Is
looking forward to further discussing with SHINE Medical Technologies how these
aspects can be realized.
To conciude, on behalf of the Netherlands and Groningen I want to express a
genuine warm welcome to SHINE and I hope that this letter will help you in
making the best choice.
Yours since

T. van Arx
Minister for Medical Care and Sport

Page 2 of 2